SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's website at www.celgene.com.
Thursday, June 2, 2016, Celgene will present at the Sanford C Bernstein Strategic Decisions Conference in New York City at 3 pm ET
Wednesday, June 8, 2016, Celgene will present at the Goldman Sachs Healthcare Conference in Los Angeles at 12:20 pm ET
Thursday, June 9, 2016, Celgene will present at the Jefferies Healthcare Conference in New York City at 2 pm ET
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, FaceBook and YouTube.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160520005079/en/
Patrick E. Flanigan III, 908-673-9969
Corporate VP, Investor Relations
Brian Gill, 908-673-9530
VP, Corporate Communications
Source: Celgene Corporation
News Provided by Acquire Media